

COBRE/DEPT. OF TROPICAL MEDICINE SEMINAR

Clinical and Preclinical Development of a Recombinant Subunit Vaccine for Dengue

Beth-Ann Griswald Coller, Ph.D.

*Executive Director, Global Clinical Development
Merck & Co., Inc.
North Wales, Pennsylvania*

Dr. Beth-Ann Coller Ph.D., Executive Director with Merck and Co., and former Senior Vice President for Research and Development at Hawaii Biotech, Inc., will present an overview of the most recent clinical and preclinical results for the Hawaii Biotech/Merck dengue vaccine candidate. Dr. Coller received her Ph.D. in 1993 from the University of Nebraska Medical Center, where she studied the molecular virology of picornaviruses. She then joined Hawaii Biotech where her research focused on development of recombinant subunit flavivirus vaccines. In 1999, Dr. Coller joined GlaxoSmithKline Biologicals in Rixensart Belgium where she was the j@10(e)-3(ra3(v)8(aQhe)m)-6(e)-3(r jo)9oled6(o)-3(l)n23.4 241.73 5